TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00807768

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3-Dimensional Conformal Radiation Therapy
Description: Undergo pelvic radiation therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo pelvic radiation therapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Internal Radiation Therapy
Description: Undergo vaginal cuff brachytherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Internal Radiation Therapy
Description: Undergo vaginal cuff brachytherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02288663

Intervention type: OTHER
Group type: OTHER
Intervention: measurement of morphological parameters
Description: measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: a blood sample
Description: One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: albumin or blood in urine
Description: dipstick analysis for albumin or blood in urine

Intervention type: DEVICE
Group type: OTHER
Intervention: Dual X-ray absorptiometry (DXA)
Description: measurement of lean body mass by whole-body DXA

Intervention type: DEVICE
Group type: OTHER
Intervention: Bioelectric Impedance Spectroscopy (BIS)
Description: measurement of lean body mass by BIS

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 51Cr-EDTA plasma clearance
Description: measurement of 51Cr-EDTA plasma clearance to determine GFR
Study: NCT01143818

Intervention type: DRUG
Intervention: AndroGel (testosterone gel) 1%
Description: AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
Study: NCT01142960

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Starch
Description: 1350mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycium Barbarum
Description: 1350mg/day
Study: NCT02860676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cirmtuzumab
Description: cirmtuzumab, dose based on ongoing phase 1 trial, q14days x 4 doses, then q28 days x 4 doses, until disease progression.
Study: NCT03484780

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VisONE ADS
Description: VisONE stimulator and leads for delivering continual Synchronized Diaphragmatic Stimulation
Study: NCT01365897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: Modafinil 200mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Modafinil
Description: Modafinil 200mg
Study: NCT03837132

Intervention type: BEHAVIORAL
Intervention: Palliative care assessment
Description: Patients with advanced pancreatic cancer will have regular palliative care assessment with palliative care team
Study: NCT02283203

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: APOTEL max
Description: The study drug is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein.
Study: NCT01287507

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin (bovine origin)
Description: Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
Study: NCT02283203

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
Study: NCT00304863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Description: This arm will receive the additional probiotic of lactobacillus GG
Study: NCT02837042

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered intravenously every 3 weeks.
Study: NCT04015674

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise group
Description: Aerobic exercise on a stationary bicycle

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise group
Description: Aerobic exercise on a stationary bicycle

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: In a rest

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control group
Description: In a rest
Study: NCT03033199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic Agent
Description: probiotic capsules containing three viable and freezedried strains-Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg per day, 4 consecutive days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 40 mg per day, 4 consecutive days
Study: NCT01340599

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study: NCT01287507

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactoferrin (bovine origin)
Description: Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
Study: NCT01736176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-Carbidopa Intestinal Gel
Description: Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.~The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levodopa-carbidopa Immediate Release (LC-IR) Tablets
Description: After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
Study: NCT02409576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Expanded , Activated NK cells
Description: 1. Chemotherapy - Each patient will receive immunosuppressive chemotherapy before infusion of NK cells.~   Day -7 Cyclophosphamide at 60mg/kg Day -6 Fludarabine at 25mg/m2 daily for 5 days~2. Radiation - Each patient will receive radiation within 48 hr of NK cell infusion to make the tumor cells more sensitive to NK cell killing Radiation 2Gy~3. Cytokine support - Each pateint will receive IL-2 to support NK cell activation and expansion in vivo Day -1 alternate day for a total of 6 doses~4. NK cells - Expanded activated haploidentical NK cells will be infused on day 0.
Study: NCT03389009

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Biomicroscopy of anterior segment of the eye
Description: 5150 Vumax (Sonomed, USA) under standard illumination

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Biomicroscopy of anterior segment of the eye
Description: 5150 Vumax (Sonomed, USA) under standard illumination
Study: NCT02473354

Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil
Description: The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air \[21% Oxygen\]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.

Intervention type: DRUG
Group type: OTHER
Intervention: Oxygen
Description: Remifentanil will be administered under normal oxygen (normoxia) and increased oxygen (hyperemic) conditions.
Study: NCT03676712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scoliosis brace
Description: Wear at least 18 hours a day
Study: NCT04561960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride toothpaste
Description: Fluoridated paste containing 1450ppm NaF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toothpaste Product
Description: Non Fluoridated toothpaste with extract of miswak ( Dabur, miswak tooth paste)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrush
Description: Colgate classic clean Soft bristled toothbrushes, 19.05 x 1.27 x 1.91 cm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Toothbrush
Description: Colgate classic clean Soft bristled toothbrushes, 19.05 x 1.27 x 1.91 cm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miswak Stick
Description: A miswak stick of 15 cm length
Study: NCT02473354

Intervention type: DRUG
Group type: OTHER
Intervention: Carbon dioxide
Description: Carbon dioxide is used as part of the hypercapnia ventilatory response measurement (HCVR)
Study: NCT02590939

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CEFALY Active
Description: Active external trigeminal nerve stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CEFALY Placebo
Description: Placebo external trigeminal nerve stimulation
Study: NCT00763347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-619
Description: SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-619
Description: SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-619
Description: SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYR-619
Description: SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin
Description: Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
Study: NCT01147705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same appearance/dosing as active drug.
Study: NCT02190812

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Forearm supporter
Description: The forearm supporter be use in tennis elbow.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grip ball
Study: NCT03960476

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlanYourLifespan.org
Description: The study intervention is a web-based planning tool, PlanYourLifespan.org
Study: NCT02782533

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation V3
Study: NCT00641407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPL insulin
Description: Starting dose 10 IU bedtime and then titration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin glargine
Description: 10 IU bedtime and then titration
Study: NCT00418132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
Study: NCT00673140

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far Infrared Radiation (5μm to 20μm wavelength)
Description: Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Far infrared radiation
Description: Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.
Study: NCT00418132

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo thalidomide
Description: Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.
Study: NCT03359642

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample
Description: 14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood sample
Description: 14 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stool samples
Description: Study of the fecal microbiota

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stool samples
Description: Study of the fecal microbiota

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food questionnaire
Description: food questionnaire on the seven days before the collection

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: food questionnaire
Description: food questionnaire on the seven days before the collection

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: colonoscopy
Description: Only for patients with ulcerative colitis (in routine care)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: colonoscopy
Description: Only for patients with ulcerative colitis (in routine care)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VOCs profile
Description: Volatile Organic Compounds (VOCs) profile obtained by mass spectrometry

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VOCs profile
Description: Volatile Organic Compounds (VOCs) profile obtained by mass spectrometry
Study: NCT03496948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeGeCoach
Description: 12-month long telephone health coaching carried out by specially trained coaches. The health coaching is a patient-centered approach based on motivational interviewing, shared decision-making and active listening techniques. Primary care physicians will be constantly involved receiving regular health reports from the coach.~The walking exercise is based on the principle of interval training. Patients will continuously wear an activity monitor device to review their exercise performance and for remote exercise monitoring by the coach. This activity information will be regularly reviewed by the coach to ensure that the patient adheres to the individual walking exercise prescription.
Study: NCT01920919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02385084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2409021
Description: Administered orally
Study: NCT04119856

Intervention type: OTHER
Group type: OTHER
Intervention: Affiliation with the outgoing lung team
Description: The work of the outgoing lung team takes place in the patient's home and involves the following:~* The outgoing lung team teaches the patients, relatives and primary care staff about symptoms, treatments and instructions related to COPD.~* The patients, relatives and primary care staff can contact the outgoing lung team by telephone day and night.~* The patients report symptoms and measurements to the outgoing lung team using telemedicine as patient reported outcomes.~* The outgoing lung team initiates appropriate treatment by telephone or a home visit. The outgoing lung team always consults a doctor from the Department of Respiratory Diseases and Allergy before initiating treatment.~* The outgoing lung team initiates acute consultations at Department of Respiratory Diseases and Allergy based on patient reported outcomes, home visit or telephone call.
Study: NCT00689728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: LY2127399 will be administered as a single IV infusion over 30 minutes.
Study: NCT01340599

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunoenzyme technique
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: immunoenzyme technique
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo radical prostatectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: therapeutic conventional surgery
Description: Undergo radical prostatectomy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: high performance liquid chromatography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: mass spectrometry
Description: Correlative studies
Study: NCT00700505

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FlowPants(R) Garment
Description: The garment is shaped like a pair of boxer briefs. Garment heating is battery-powered.~The garment is activated and begins to heat up 5-15 minutes prior to voiding.
Study: NCT00689728

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: LY2127399 will be administered as a single IV infusion over 30 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as a single IV infusion over 30 minutes.
Study: NCT05033106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab, Ranibizumab
Description: • A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant and 0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye 1 mm posterior to the superior/inferior temporal limbus via 30 G needle. The two injections are done sequentially on two consecutive days starting with the eye of more advanced disease.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab, Ranibizumab
Description: • A dose of 0.25 mg/0.025 mL ranibizumab (Lucentis) is injected in the right eye of the infant and 0.625 mg/0.025 mL bevacizumab is injected into the vitreous cavity of the left eye 1 mm posterior to the superior/inferior temporal limbus via 30 G needle. The two injections are done sequentially on two consecutive days starting with the eye of more advanced disease.
Study: NCT03271905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol sulfate and ipratropium bromide
Description: Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol sulfate and ipratropium bromide
Description: Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: salbutamol sulfate and ipratropium bromide
Description: Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh nebulization
Description: Nebulization with Mesh device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh nebulization
Description: Nebulization with Mesh device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mesh nebulization
Description: Nebulization with Mesh device.
Study: NCT00306709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: culturally adapted behavior change
Description: Behavior change strategies which have been modified to include spirituality, AA cultural materials and examples woven into the lesson plans, and sustained peer support.
Study: NCT03033264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: 10 mg of a Dinoprostone vaginal insert.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: 10 mg of a Dinoprostone vaginal insert.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double lumen cervical ripening balloon.
Description: Double lumen cervical ripening balloon.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Double lumen cervical ripening balloon.
Description: Double lumen cervical ripening balloon.
Study: NCT02254395

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation
Study: NCT00498355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.